Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland
Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 Mutation Assay in both the United Kingdom (UK) and Switzerland. The LeukoStrat CDx FLT3 Mutation Assay aids in the accurate detection of FLT3 mutations, empowering clinicians to make informed treatment decisions. This milestone ensures expanded accessibility of critical treatments to patients diagnosed with acute myeloid leukemia (AML).
Regulatory compliance in the UK and Switzerland has been achieved through Invivoscribe’s UK Responsible Person (UKRP) and Swiss Authorized Representative (CH-REP), ensuring full adherence to national regulatory frameworks. Both the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, and Swissmedic in Switzerland—have officially registered this CDx assay. These agencies are responsible for ensuring product safety, efficacy, and compliance with post-market surveillance requirements.
AML is an aggressive and rapidly progressing hematologic malignancy. Making timely and accurate detection of actionable mutations such as FLT3 is critical and essential for optimizing patient outcomes. The LeukoStrat CDx FLT3 Mutation Assay enables rapid same day results and precise identification of FLT3 mutations, which are associated with poor prognosis and targeted treatment options. By providing standardized, reliable and timely FLT3 mutation testing, the assay plays a critical role in precision medicine, helping guide therapeutic decisions and improving the management of AML worldwide.
This registration reinforces Invivoscribe’s commitment to expanding access to high quality, regulatory compliant companion diagnostics that enable clinicians and patients to benefit from cutting-edge advancements in molecular testing.
For more information about the LeukoStrat CDx FLT3 Mutation Assay and Invivoscribe’s comprehensive portfolio of precision diagnostics, please visit www.invivoscribe.com or contact us at inquiry@invivoscribe.com and follow us on Linked In.
EU Intended Use
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based in vitro diagnostic test designed to detect internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML). The LeukoStrat CDx FLT3 Mutation Assay may be used as a companion diagnostic for the following therapeutic:
In regions where XOSPATA® (gilteritinib fumarate) is available, the LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the assessment of patients with AML for whom XOSPATA® (gilteritinib fumarate) treatment is being considered.
In regions where VANFLYTA® (quizartinib hydrochloride) is available, the LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the assessment of patients with FLT3-ITD+ AML for whom VANFLYTA® (quizartinib hydrochloride) treatment is being considered.
The qualitative, non-automated test is for use on the 3500xL or 3500xL Dx Genetic Analyzers.
About Invivoscribe
Invivoscribe is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For nearly thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the US, Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326336959/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer survey reveals key drivers of job satisfaction among Dutch accounting professionals6.8.2025 08:00:00 CEST | Press release
Findings highlight the importance of workplace atmosphere, meaningful work, and automation in boosting employee happiness and retention Wolters Kluwer Tax & Accounting Netherlands today released the results of its latest survey, “Work Pressure or Job Satisfaction?”, offering a revealing look into what drives happiness—and frustration—among accounting professionals in the Netherlands. The survey, conducted in May 2025, gathered insights from professionals across a range of roles and firm sizes, providing a snapshot of the sector’s evolving expectations and challenges. “The future of the accounting profession calls for greater focus on employee well-being and educational innovation,” said Jeffrey Smit, Vice President & General Manager, Wolters Kluwer Tax & Accounting, Europe Region West. “True gains come from sustainable employability, future-focused expertise, and job satisfaction. Today’s accountant is no longer just a number-cruncher, but a savvy advisor who brings together data, tech
The GTDC, CONTEXT and IDC Forge Unprecedented Global Alliance to Deliver Technology Sales Data6.8.2025 04:00:00 CEST | Press release
First-of-its-kind collaboration will result in like-for-like, actionable data for IT vendors and distributors across Asia Pacific, North America, Europe, and the Middle East markets Three powerhouse leaders in the global distribution and data intelligence sector are partnering to create the first and only data source that will deliver comprehensive sell-through insights across Asia Pacific, North America, Europe, and the Middle East. The collaboration will deliver the definitive global source of technology sales-through data across key markets, providing vendors and distributors with an unparalleled 360-degree view of market trends. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805421998/en/ IDC, GTDC and CONTEXT, powerhouse leaders in the global distribution and data intelligence sector, are partnering to create the first and only data source that will deliver comprehensive sell-through insights across Asia Pacific, Nor
The Hackett Group® and Celonis Partner to Accelerate ROI With Unmatched AI + Process Intelligence Solutions5.8.2025 23:18:00 CEST | Press release
The Hackett Group, Inc. (NASDAQ: HCKT), a leading generative artificial intelligence (Gen AI) consultancy and executive advisory firm, today announced a collaboration with Celonis, a global leader in process mining, to deliver intelligent enterprise automation that drives measurable business results at unprecedented speed. Using Celonis process intelligence and The Hackett Group’s AI XPLR™ and ZBrain™ platforms – that leverage The Hackett Group’s globally recognized enterprise benchmarking and business transformation IP – companies can compare their performance against Digital World Class® performance standards. This will allow clients to quickly identify the greatest ROI opportunities and harness unmatched process intelligence and agentic workflow solutions to achieve their value realization objectives. The partnership delivers: Clarity on the right tech investments: Combining The Hackett Group’s industry benchmarks with Celonis process intelligence and its own benchmarks on leading m
IFF Reports Second Quarter 2025 Results5.8.2025 22:26:00 CEST | Press release
Reaffirms Full Year 2025 Financial GuidanceLeverage Reduced to 2.5x; Announces new $500M Share Repurchase AuthorizationEnters into Definitive Agreement to Sell Soy Crush, Concentrates & Lecithin Business; Evaluating Strategic Alternatives for Food Ingredients Segment IFF (NYSE: IFF) reported financial results for the second quarter ended June 30, 2025. Management Commentary “IFF’s second-quarter results reflect the progress we are making to strengthen our business and advance our strategic agenda,” said Erik Fyrwald, CEO of IFF. “Our teams delivered top-line growth and improved profitability, driven by disciplined execution and a strong focus on productivity. We also made strides in reshaping our portfolio by closing the divestitures of Pharma Solutions and Nitrocellulose, and successfully completing our debt tender offering - reducing leverage to 2.5x, ahead of our target and reinforcing our financial position.” “Additionally, we announced the expected divestiture of our soy crush, co
Cooler Master’s MasterHUB Wins Red Dot Award for Design Excellence5.8.2025 21:36:00 CEST | Press release
Modular Control Deck Honored in 2025 Brands & Communication Category Cooler Master, a global leader in innovative thermal solutions and PC hardware, today announced that MasterHUB has won the Red Dot Award in the 2025 Brands & Communication Design category. The Red Dot is an internationally recognized symbol of outstanding design quality, awarded by a jury of global design experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805404259/en/ Cooler Master's Award-Winning MasterHUB Stream Deck. This recognition highlights Cooler Master’s FreeForm 2.0 design philosophy, which empowers users to build personalized, modular systems that evolve with their needs. MasterHUB embodies this approach by offering a flexible foundation for streamers, editors, and creatives to shape their own workflows. “MasterHUB was designed to grow with you,” said Matteo Stracciari, General Manager at Cooler Master. “Whether you're mixing audio, edit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom